Management of panic disorder

Expert Review of Neurotherapeutics

Volumn 5, Issue 2, 2005, Pages 259-266

  Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Benzodiazepine; Cognitive behavioral therapy; Combined therapy; Monoamine oxidase inhibitors; Panic attacks and panic disorder; Selective serotonin reuptake inhibitors; Tricyclic antidepressant

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUNITRAZEPAM; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

AGGRESSIVENESS; ATAXIA; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DIZZINESS; DOSE CALCULATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; FOOD DRUG INTERACTION; HEART PALPITATION; HUMAN; INSOMNIA; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PANIC; PATIENT COUNSELING; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAXATION TRAINING; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; EXPERT TESTIMONY; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; PRACTICE GUIDELINES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 15944390625     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.2.259     Document Type: Review

References (37)

1. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. Panic attacks in the community. Social morbidity and health care utilization. JAMA 265, 742-746 (1991).
2. Robins LN, Regier DA. (Eds). Psychiatric Disorders in America: the Epidemiologic Catchment Area Study. Free Press, NY, USA (1991). Classic epidemiologic study used as a basis for most estimates of morbidity.
3. Weissman MM, Bland MB, Canino GJ et al. The cross-national epidemiology of panic disorder. Arch. Gen. Psych. 54, 305-309 (1997). Another classic epidemiologic study.
4. DeLoof C, Zandbergen H, Lousberg T et al. The role of life events in the onset of panic disorder. Behav. Res. Ther. 27, 461-463 (1989).
5. Rapee RM, Mattick RP, Murrell E. Impact of life events on subjects with panic disorder and on comparison subjects. Am. J. Psychiatry 147, 640-644 (1990).
6. Hirschfield RMA. Panic disorder: diagnosis, epidemiology and clinical course. J. Clin. Psychiatry 57, 3-8 (1996). Very useful review.
7. Page AC, Andrews G. Do specific anxiety disorders show specific drug problems? Aust. NZ J. Psychiatry 30, 410-414 (1996).
8. Gorman JM, Caplan JD. Comorbidity of depression and panic disorder. J. Clin. Psychiatry 57, 34-41 (1996).
9. Tyrer P, Seivewright H, Simmonds S et al. Prospective studies of cothymia (mixed anxiety-depression): how do they inform clinical practice? Eur. Arch. Psychiatry Clin. Neurosci. 251, 1153-1156 (2001).
10. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 5, 171-199 (2002). Excellent evidence-based overview of the drug treatment of all the anxiety disorders.
11. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta analysis. Int. Clin. Psychopharmacol. 10, 45-49 (1995).
12. Bakker A, van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta analysis. Acta Psychiat. Scand. 106, 163-167 (2002).
13. Otto M, Tuby K, Gould R et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am. J. Psychiatry 158, 1989-1992 (2001).
14. Lepola UM, Wade AG, Leinonen EV et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J. Clin. Psychiatry 59, 528-534 (1998).
15. Wade AG, Lepola U, Koponen HJ et al. The effect of citalopram in panic disorder. Br. J. Psychiatry 170, 549-553 (1997).
16. Rapaport M, Wolkow R, Rubin A et al. Sertraline treatment of panic disorder results of a long term study. Acta Psych. Scand. 104, 289-298 (2001).
17. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psych. Scand. 95, 153-160 (1997).
18. Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder, an acute double-blind non inferiority comparison. J. Clin. Psychiatry 65, 405-413 (2004).
19. Pollack MH, Worthington JJ, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharm. Bull. 32, 667-670 (1996).
20. Bertani A, Perna G, Migliarese G et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder, a randomized single-blind study. Pharmacopsychiatry 37, 206-210 (2004).
21. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch. Gen. Psych. 37, 51-59 (1980). One of the earliest studies to establish the use of medication in panic disorder.
22. Loerch B, Graf-Morgenstern M, Hautzinger et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br. J. Psychiatry 174, 205-212 (1999).
23. Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder moclobemide, a case in point. J. Clin. Psychopharmacol. 22, 275-284 (2002).
24. Curtis GC, Massana J, Udina C et al. Maintenance drug therapy of panic disorder. J. Psychiatr. Res. 27, 127-142 (1993).
25. Rickels K. Alprazolam extended-release in panic disorder. Expert Opin. Pharmacother. 5, 1599-1611 (2004).
26. Bouvard M, Mollard E, Guenn J et al. Study and course of the psychological profile in 77 patients experiencing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother. Psychosom. 66, 27-32 (1997).
27. Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectr. 9, 725-739 (2004). Very useful review for the practising clinician.
28. Mathew SJ, Caplan JD, Gorman JM. Management of treatment-refractory panic disorder. Pharmacol. Bull. 35, 97-110 (2001).
29. Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol. 17, 276-282 (2003).
30. Doyle A, Pollack MH. Long-term management of panic disorder. J. Clin. Psych. 65(Suppl. 5), 24-28 (2004).
31. Heuzenroeder L, Donnelly M, Haby E et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. NZ J. Psych. 38, 602-612 (2004).
32. Williams SL, Falbo J. Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav. Res. Ther. 34, 253-264 (1996).
33. Barlow DH, Gorman JM, Shear MK et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder, a randomised controlled trial. JAMA 283, 2529-2536 (2000).
34. Beck AT, Sokol L, Clark DA et al. A crossover study of focused cognitive therapy for panic disorder. Am. J. Psychiatry 149, 778-783 (1992).
35. Mavissakalian M, Michelson L. Agoraphobia, behavioral and pharmacological treatment (n = 49). Pharmacol. Bull. 19, 116-118 (1983). Establishes the efficacy of cognitive behavioral therapy.
36. Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch. Gen. Psych. 53, 689-694 (1996).
37. Bruce SE, Vasile RG, Keller, MB et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am. J. Psychiatry 160, 1432-1438 (2003).